Related Experiment Video

Updated: May 10, 2026

Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
05:11

Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities

Published on: May 10, 2024

ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma

S E Busch1, R D Moser2, K E Gurley2

  • 11] Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA, USA.

Oncogene
|June 12, 2013
PubMed

Insights

The tumor suppressor ARF is crucial in preventing non-small-cell lung cancer (NSCLC) progression. Loss of ARF accelerates tumor growth, malignancy, and metastasis in Kras-driven lung cancer models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small-cell lung carcinoma (NSCLC) is a leading cause of cancer death.
  • The CDKN2A locus, containing tumor suppressor genes INK4a and ARF, is frequently altered in NSCLC.
  • The precise function of ARF in lung cancer development is not fully understood.

Purpose of the Study:

  • To investigate the role of ARF in Kras-driven non-small-cell lung carcinoma.
  • To determine if ARF acts as a barrier against pulmonary tumorigenesis and malignant progression.

Main Methods:

  • Comparison of urethane-induced lung carcinogenesis in wild-type and Arf-knockout mice.
  • Analysis of tumor size, malignancy, morbidity, cell proliferation, and DNA damage.
  • Assessment of ARF expression in benign and malignant lung tumors.

Main Results:

  • Arf-knockout mice exhibited significantly increased lung tumor size, malignancy, and morbidity compared to wild-type mice.
  • Pulmonary tumors in Arf-knockout mice showed elevated cell proliferation and DNA damage.
  • A subset of tumors in Arf-knockout mice displayed dedifferentiation, metastasis, and sarcomatoid features, a novel finding in mouse models.
  • ARF expression was high in benign adenomas but reduced in malignant adenocarcinomas, correlating with p21(CIP1) expression.

Conclusions:

  • ARF functions as a critical tumor suppressor in Kras-driven NSCLC.
  • ARF induction is an early event in lung tumorigenesis, acting as a barrier to tumor growth and progression.
  • Loss of ARF facilitates malignant transformation and metastasis in the lung.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...